In vitro diagnostic medical devices (IVD)

In vitro diagnostic medical devices (IVD) must achieve the performance declared by the manufacturer, in particular, as appropriate, in terms of analytical sensitivity, diagnostic sensitivity, analytical specificity, diagnostic specificity, accuracy, repeatability, reproducibility, including the control of the known relevant interferences with other products, and with regard to the detection limit of the examined parameter.
The manufacturer demonstrates that these requirements are met by a combination of relevant scientific literature and performance studies. Depending on the type of IVD, the validation of this data is certified by a notified body or by self-certification.

 

New In Vitro Medical Device Regulation (IVDR)

 

As of May 26 2022, the European Regulation (EU) 2017/746 on In Vitro Medical Devices (IVDR) comes into force. The IVDR introduces a major update of the regulatory framework in the European Union and brings about several changes to the scope of performance studies, clinical studies with in vitro medical devices, that must be submitted for approval/notification, the submission processes for initial application and substantial modifications, submission dossier contents and safety reporting. 

Below you can find the links to several Belgian and European guidelines and documents concerning performance studies under the IVDR. All questions concerning these studies may be sent per mail to ct.rd@fagg.be

Please note that the Belgian guideline and this website will be updated regularly according to the most recent information. Please make sure to always consult the latest version of each document.

European legislation and guidelines 
•    European Regulation (EU) 2017/746 on In Vitro Medical Devices (IVDR)
•    The MDCG 2022-2 guidance on general principles of clinical evidence for IVDs

•    MDCG 2022-10 – Q&A(link is external) on the interface between Regulation (EU) 536/2014 on clinical trials for medicinal products for human use (CTR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)

Belgian legislation 
-    Law of 15/06/2022 concerning medical devices for in-vitro diganostics 
-    Royal Decree of 15/09/2022 

Belgian guidelines and documents  

•    Guideline on Submission Processes of Performance Studies according to IVDR in Belgium (version 3.0). This document aims at providing guidance for the different submission processes for clinical investigations under the new regulation from a national point of view.

•    Zip-folder structure for initial performance study applications including relevant templates              

•    Template for the list of submitted documents – initial submission
•    Template for the list of submitted documents – substantial modifications
•    Application form – initial submission (duplicated section 3 - duplicated section 4 - duplicated section 5)
•    Application form – substantial modifications
•    Template List of GSPR

Ongoing performance studies


IVD performance studies notified to the FAMHP before May 26th 2022 still fall under the IVD directive, there is no need for a resubmission under IVDR.
 

Guidelines

Amendments

Notification of termination of the Clinical Investigation

Contact 

ct.rd@fagg.be

Last updated on 20/12/2022